HRS-4357

HRS-4357 is an investigational agent whose form is not stated in the registry developed by Jiangsu HengRui Medicine. Its target is PSMA (the sponsor names PSMA (inferred from trial population)). ClinicalTrials.gov describes the intervention as: HRS-4357 injection are administered each time, with dosing for 4 to 6 cycles. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07311694 (A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer), in prostate cancer. The largest, NCT07311694, plans to enrol 370 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.